Cryoablation: A promising non-operative therapy for low-risk breast cancer - 08/12/20
Abstract |
Background |
The aim of this study was to evaluate the feasibility of cryoablation for early-stage low-risk breast cancer without tumor resection.
Methods |
Women diagnosed with ER+, PR+, and HER2-infiltrating ductal carcinomas ≤1.5 cm were treated with cryoablation. The non-surgical procedure used a Visica® 2 Treatment System with ultrasound guidance for ablation of the tumor with a 1 cm margin. Patients were monitored at 6-month intervals by MRI, mammogram, and ultrasound.
Results |
Twelve patients with unifocal breast cancer were treated with cryoablation for local control without follow-up tumor resection. All patients received adjuvant endocrine therapy, and none had radiation. The median follow-up was 28.5 (range = 4–41) months with 11 patients having at least one six-month follow-up. All imaging modalities showed complete ablation of target zone 11/11 (100%). Four patients (33.3%) have been followed up for ≥ 2 years with no local failure or residual disease.
Conclusion |
Cryoablation of early-stage low-risk (ER+, PR+, and HER2-) breast cancer is a safe alternative to surgery.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Cryoablation of ER+, PR+, and HER2-invasive ductal carcinoma ≤15 mm offers optimal local control. |
• | Cryoablation is a feasible alternative to surgery in low-risk breast cancer. |
• | Breast imaging at 6 months showed no residual or recurrent disease. |
• | Breast MRI has the highest negative predictive value among breast imaging modalities. |
Keywords : Breast cancer, Cryoablation, Invasive ductal carcinoma, Early-stage, ER+PR+HER2-
Plan
Vol 221 - N° 1
P. 127-133 - janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?